Leaflet: information for the user
Ezetimiba/Simvastatina Viso Pharmaceutical 10 mg/10 mg tablets EFG
Ezetimiba/Simvastatina Viso Pharmaceutical 10 mg/20 mg tablets EFG
Ezetimiba/Simvastatina Viso Pharmaceutical 10 mg/40 mg tablets EFG
Ezetimiba/Simvastatina Viso Pharmaceutical 10 mg/80 mg tablets EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents ofthe leaflet
6. Contents of the package and additional information
This medicationcontains the active principles ezetimiba and simvastatina.It is used to reduce total cholesterol, "bad" cholesterol (LDL cholesterol) and certain fatty substances called triglycerides that circulate in the blood. Additionally, it increases the concentrations of "good" cholesterol (HDL cholesterol).
Ezetimiba/simvastatinaacts by reducing cholesterol in two ways. The active principle ezetimiba reduces the cholesterol absorbed in the digestive tract. The active principle simvastatina, which belongs to the group of "statins", inhibits the production of cholesterol produced by the body itself.
Cholesterol is one of the fatty substances found in the bloodstream. Its total cholesterol is mainly composed of LDL and HDL cholesterol.
LDL cholesterol is often referred to as "bad" cholesterol because it can accumulate in the walls of your arteries, forming plaques. Over time, this accumulation of plaque can cause a narrowing of the arteries. This narrowing can make blood flow to vital organs such as the heart and brain slower or interrupted. This interruption of blood flow can cause a heart attack or stroke.
HDL cholesterol is often referred to as "good" cholesterol because it helps prevent bad cholesterol from accumulating in the arteries and protects them from heart disease.
Triglycerides are another type of fat in your blood that can increase the risk of heart disease.
Ezetimiba/simvastatinais used in patients who cannot control their cholesterol levels solely with diet. While taking this medication, you must follow a cholesterol-reducing diet.
Ezetimiba/simvastatinais used, along with a cholesterol-reducing diet,if you have:
This medicationdoes not help you lose weight.
Do not take Ezetimiba/Simvastatina Viso Farmacéutica if:
Do not take more than 10/40 mg of ezetimiba/simvastatina if you are taking lomitapida (used to treat rare and severe cholesterol disorders)
Consult your doctor if you are unsure if your medication is mentioned above.
Warnings and precautions
Inform your doctor:
Your doctor will perform a blood test before you start taking ezetimiba/simvastatina and also if you have any symptoms of liver problems while taking ezetimiba/simvastatina. This is to check how well your liver is working.
Your doctor may also want to perform blood tests to check how well your liver is working after you start taking ezetimiba/simvastatina.
While you are taking this medication, your doctor will monitor if you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high levels of sugar and fat in your blood, being overweight and high blood pressure.
Talk to your doctor if you have a severe lung disease.
Avoid the combined use of ezetimiba/simvastatina and fibrates (certain medications to reduce cholesterol), as the combined use of ezetimiba/simvastatina and fibrates has not been studied.
Consult your doctor immediately if you experience pain, sensitivity to pressure or unexplained muscle weakness. This is because in rare cases, muscle problems can be severe, including muscle failure which causes kidney damage; and very rarely, deaths have occurred.
The risk of muscle failure is higher with high doses of ezetimiba/simvastatina, especially the dose of 10/80 mg. The risk of muscle failure is also higher in certain patients. Inform your doctor in the following situations:
Also inform your doctor or pharmacist if you experience persistent muscle weakness. Further tests and additional medications may be necessary to diagnose and treat this condition.
Children and adolescents
Other medications and Ezetimiba/Simvastatina Viso Farmacéutica
Inform your doctor if you are taking, have taken recently or may need to take any other medication with any of the following active ingredients. Taking ezetimiba/simvastatina with any of the following medications may increase the risk of muscle problems (some of which are already included in the section above "Do not take Ezetimiba/Simvastatina Viso Farmacéutica if").
As with the medications mentioned above, inform your doctor or pharmacist if you are taking or have taken recently other medications, even those purchased without a prescription. In particular, inform your doctor if you are taking any of the following:
You should also inform any doctor who prescribes a new medication that you are taking ezetimiba/simvastatina.
Taking Ezetimiba/Simvastatina Viso Farmacéutica with food and drinks
Orange juice contains one or more components that alter the metabolism of some medications, including ezetimiba/simvastatina. You should avoid consuming orange juice, as it may increase the risk of muscle problems.
Pregnancy and breastfeeding
Do not take this medication if you are pregnant, trying to become pregnant or think you may be pregnant. If you become pregnant while taking ezetimiba/simvastatina, stop taking it immediately and inform your doctor. Do not take ezetimiba/simvastatina if you are breastfeeding, as it is unknown whether this medication passes into breast milk.
Consult your doctor or pharmacist before using any medication.
Driving and operating machines
Ezetimiba/simvastatina is not expected to interfere with your ability to drive or operate machines. However, some people may experience dizziness after taking ezetimiba/simvastatina.
Ezetimiba/Simvastatina Viso Farmacéutica contains lactose
This medication contains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Ezetimiba/Simvastatina Viso Farmacéutica contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; that is, it is essentially "sodium-free".
Your doctor will determine the appropriate dose for you, based on your current treatment and personal risk situation.
The tablets do not have a notch and should not be divided.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Adults: the dose is1 tabletof ezetimiba/simvastatina once a day by mouth.
Use in adolescents(10 to 17 years old): the dose is1 tabletof ezetimiba/simvastatina once a day by mouth (do not exceed a maximum dose of 10mg/40mg once a day).
The ezetimiba/simvastatina 10mg/80mg dose is only recommended for adult patients with very high cholesterol levels and a high risk of heart disease problems who have not achieved treatment goals with lower doses.
Take ezetimiba/simvastatina at night. You can take it with or without food.
If your doctor has prescribed ezetimiba/simvastatina along with another cholesterol-lowering medication that contains the active ingredient colestiramine or any other bile acid sequestrant, you should take ezetimiba/simvastatina at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you take more Ezetimiba/Simvastatina Viso Farmaceuticathan you should
If you forgot to take Ezetimiba/Simvastatina Viso Farmaceutica
If you interrupt the treatment with Ezetimiba/Simvastatina Viso Farmaceutica
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them (see section 2. What you need to know before starting to take Ezetimiba/Simvastatina Viso Farmaceutica).
The following frequent side effects (can affect up to 1 in 10 people) have been reported:
The following infrequent side effects (can affect up to 1 in 100 people) have been reported:
In addition, the following side effects have been reported in people taking ezetimiba/simvastatina or medications containing the active principles ezetimiba or simvastatina:
With some statins, the following additional adverse events have been reported:
Consult your doctor if you experience weakness in your arms or legs that worsens after periods of activity, double vision, eyelid drooping, difficulty swallowing, or difficulty breathing.
Consult your doctor immediately if you experience unexplained muscle pain, pressure sensitivity, or weakness. This is because, in rare cases, muscle problems can be severe, including muscle failure, which can cause kidney damage; and very rarely, deaths have occurred.
Reporting of side effects:
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:
https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box or in the bottle after the CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25 °C.
Blister: Store the blister in the outer packaging to protect it from moisture.
Bottles: Keep the bottle perfectly closed and store in the outer packaging to protect it from moisture.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE point of the pharmacy.Ask your pharmacist how to dispose of the containers and medicines you no longer need if you are unsure. By doing so, you will help protect the environment.
Composition of Ezetimiba/Simvastatina Viso Pharmaceutical
The active ingredients are ezetimiba and simvastatina. Each tablet contains 10 mg of ezetimiba and 10 mg, 20, 40 mg or 80 mg of simvastatina.
The other components are: lactose monohydrate, microcrystalline cellulose (E 460), hypromellose, croscarmellose sodium (E 468), propyl gallate (E 310), butylated hydroxyanisole (E 320), citric acid monohydrate (E 330), sodium lauryl sulfate, magnesium stearate (E 470b).
See also section 2 “What you need to know before taking Ezetimiba/Simvastatina Viso Pharmaceutical”
Appearance of Ezetimiba/Simvastatina Viso Pharmaceutical and packaging contents
10 mg/ 10 mg:
White to off-white, uncoated tablets in capsule shape, with “G” engraved on one face and “321” on the other face, approximately 8.5 mm in length and 4.25 mm in width.
10 mg/ 20 mg:
White to off-white, uncoated tablets in capsule shape, with “G” engraved on one face and “322” on the other face, approximately 10.7 mm in length and 5.3 mm in width.
10 mg/ 40 mg:
White to off-white, uncoated tablets in capsule shape, with “G” engraved on one face and “323” on the other face, approximately 14.0 mm in length and 6.0 mm in width.
10 mg/ 80 mg:
White to off-white, uncoated tablets in capsule shape, with “G” engraved on one face and “324” on the other face, approximately 17.5 mm in length and 7.5 mm in width.
Ezetimiba/Simvastatina Viso Pharmaceutical 10 mg/10 mg, 10 mg/20 mg, 20 mg/40 mg and 10 mg/80 mg are presented in PVC-Aluminio-OPA / Aluminio of 7, 10, 14, 28, 30, 49, 50, 56, 84, 90, 98, multiple packaging containing 98 (2 boxes of 49), 100, 196, 300 or 392 tablets and HDPE bottles of 90 tablets (only Ezetimiba/Simvastatina Viso Pharmaceutical 10 mg/40 mg). The tablets packaged in HDPE bottles include a desiccant that protects the tablets from moisture. The desiccant should not be taken.
Only some packaging sizes may be commercially available.
Marketing Authorization Holder
Glenmark Arzneimittel GmbH
Industriestr. 31
82194 Gröbenzell
Germany
Responsible for manufacturing
Glenmark Pharmaceuticals s.r.o.
Fibichova 143, Vysoké Mýto
566 17
Czech Republic
O
Pharmadox Healthcare Ltd
KW20A Kordin Industrial Park
Paola PLA3000
Malta
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Viso Farmacéutica, S.L.U.
c/ Retama 7, 7ª Planta
28045 Madrid
Spain
This medication is authorized in the member states of the European Economic Area with the following names:
Netherlands:Ezetimibe/Simvastatine Glenmark 10 mg/10 mg tablets
Ezetimibe/Simvastatine Glenmark 10 mg/20 mg tablets
Ezetimibe/Simvastatine Glenmark 10 mg/40 mg tablets
Ezetimibe/Simvastatine Glenmark 10 mg/80 mg tablets
Germany:Ezetimibe/Simvastatine Glenmark 10 mg/10 mg tablets
Ezetimibe/Simvastatine Glenmark 10 mg/20 mg tablets
Ezetimibe/Simvastatine Glenmark 10 mg/40 mg tablets
Ezetimibe/Simvastatine Glenmark 10 mg/80 mg tablets
Czech Republic:Glezisim
Slovakia:Glezisim 10 mg/10 mg tablets
Glezisim 10 mg/20 mg tablets
Glezisim 10 mg/40 mg tablets
Glezisim 10 mg/80 mg tablets
Norway:Ezetimib/Simvastatin Glenmark 10 mg/20 mg tablets
Ezetimib/Simvastatin Glenmark 10 mg/40 mg tablets
Denmark:Ezetimib/Simvastatin Glenmark
Sweden:Ezetimib/Simvastatin Glenmark 10 mg/10 mg tablets
Ezetimib/Simvastatin Glenmark 10 mg/20 mg tablets
Ezetimib/Simvastatin Glenmark 10 mg/40 mg tablets
Ezetimib/Simvastatin Glenmark 10 mg/80 mg tablets
Last review date of this leaflet: June 2023
Other sources of information
The detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.